IP Library Granted Patent US 8,796,440
Granted Patent B2
US 8,796,440 · App. 13/392,954 · Granted Aug 5, 2014

Promote system for regulatable gene expression in mammalian cells

Inventor: Feng Yao (Needham, MA)
Assignee: The Brigham and Women's Hospital, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,440
App. No.
13/392,954
Granted
Aug 5, 2014
Kind
B2
Abstract

The present invention is directed to a bidirectional human cytomegalovirus (hCMV) promoter that can be used to promote transcription on both strands of a double stranded DNA molecule. When used as part of a system that includes tet operator and the gene coding for the tet repressor, the promoter can be used to induce mammalian gene expression in a highly regulated way.

Claims (13)

1. A bidirectional promoter system derived from the hCMV major immediate-early promoter and comprising the structure X-Y-Z or X-Z, wherein:

X is a sequence that is complementary to 29-130 consecutive nucleotides at the 3′ end of SEQ ID NO:2, and is located at the 5′ end of Y or Z but in a reverse orientation;

Y is a nucleotide linker sequence that is not critical to promoter activity and that is 1-200 nucleotides in length; and

Z comprises 500-604 contiguous nucleotides extending from the start site of transcription of the sequence shown as SEQ ID NO:2 in the 3′ to 5′ direction and is located at the 3′ end of Y or X, terminating at the start site of transcription.

2. The bidirectional promoter system of claim 1 , wherein Y is 1-100 nucleotides in length.

3. The bidirectional promoter system of claim 1 , wherein Y is 1-40 nucleotides in length.

4. The bidirectional promoter system of claim 1 , wherein X is a sequence that is complementary to 80-110 consecutive nucleotides at the 3′ end of SEQ ID NO:2, terminating at the start site of transcription.

5. The bidirectional promoter system of claim 1 , wherein X is a sequence that is complementary to 94-108 consecutive nucleotides at the 3′ end of SEQ ID NO:2, terminating at the start site of transcription.

6. The bidirectional promoter system of claim 1 , wherein said promoter is operably linked to a gene located 3′ to Z.

7. The bidirectional promoter system of claim 6 , wherein Y is 1-100 nucleotides in length.

8. The bidirectional promoter system of claim 6 , wherein Y is 1-40 nucleotides in length.

9. The bidirectional promoter system of claim 6 , wherein X is a sequence that is complementary to 80-110 consecutive nucleotides at the 3′ end of SEQ ID NO:2, terminating at the start site of transcription.

10. The bidirectional promoter system of claim 6 , wherein X is a sequence that is complementary to 94-108 consecutive nucleotides at the 3′ end of SEQ ID NO:2, terminating at the start site of transcription.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 7, 2012
From: BRIGHAM & WOMEN'S HOSPITAL, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029258/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2012
From: YAO, FENG
To: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Reel/Frame 027849/0455 →
Continuity (2)
Provisional Application 61272193 · Aug 31, 2009
Related Publication 20120190106A1 · Jul 26, 2012